Chemistry: analytical and immunological testing – Involving producing or treating antigen or hapten
Reexamination Certificate
2007-07-24
2007-07-24
Le, Long V. (Department: 1641)
Chemistry: analytical and immunological testing
Involving producing or treating antigen or hapten
C436S544000, C436S816000, C435S007100, C530S405000, C514S343000
Reexamination Certificate
active
10909841
ABSTRACT:
Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.
REFERENCES:
patent: 3888866 (1975-06-01), Leute et al.
patent: 4045420 (1977-08-01), Soffer et al.
patent: 4123431 (1978-10-01), Soffer et al.
patent: 4235864 (1980-11-01), Kaul et al.
patent: 4376825 (1983-03-01), Rubenstein et al.
patent: 4620977 (1986-11-01), Strahilevitz
patent: 4666837 (1987-05-01), Harford et al.
patent: 4791067 (1988-12-01), Sheiman et al.
patent: 4813924 (1989-03-01), Strahilevitz
patent: 5019384 (1991-05-01), Gefter et al.
patent: 5037645 (1991-08-01), Strahilevitz
patent: 5256409 (1993-10-01), Blincko
patent: 5268276 (1993-12-01), Holmgren et al.
patent: 5278176 (1994-01-01), Lin
patent: 5283066 (1994-02-01), Liu et al.
patent: 5760184 (1998-06-01), Swain et al.
patent: 5773003 (1998-06-01), Swain et al.
patent: 5876727 (1999-03-01), Swain et al.
patent: 6232082 (2001-05-01), Ennifar et al.
patent: 6518031 (2003-02-01), Ennifar et al.
patent: 2003/0113339 (2003-06-01), Fitzpatrick et al.
patent: 2 202 441 (1973-03-01), None
patent: 25 48 196 (1977-04-01), None
patent: 0 194 158 (1986-09-01), None
patent: 0 311 383 (1989-04-01), None
patent: 0 363 041 (1990-04-01), None
patent: 0 496 839 (1992-08-01), None
patent: 0 613 899 (2003-01-01), None
patent: 1 123 704 (1984-11-01), None
patent: WO 92/03163 (1992-03-01), None
patent: WO 92/03163 (1992-03-01), None
patent: WO 93/12111 (1993-06-01), None
patent: WO 93/23070 (1993-11-01), None
patent: WO 93/23076 (1993-11-01), None
patent: WO 93/23076 (1993-11-01), None
patent: WO 95/07992 (1995-03-01), None
patent: WO 95/27786 (1995-10-01), None
patent: WO 96/30049 (1996-10-01), None
patent: WO 96/30049 (1996-10-01), None
patent: WO 98/14216 (1998-04-01), None
patent: WO 98/14216 (1998-04-01), None
Castonguay et al. Synthesis of nornicotine analogues to use as haptens for immunoassay. J. Org. Chem 1979, vol. 44, No. 24, pp. 4332-4337.
Gastro et al., “Characterization of Antibodies to Nicotine”,Biochemical Archives, Aug. 1, 1985, pp. 173-183, vol. 1, No. 3, M.B.R. Press, Inc., US.
Abad et al., “Comparison Of A Monoclonal Antibody-Based Enzyme-Linked Immunosorbent Assay And Gas Chromatography For The Determination Of Nicotine In Cigarette Smoke Condensates” Analytical Chemistry; vol. 65, No. 32; Nov. 15, 1993; pp. 3227-3231.
Ambre et al., “A Kinetic Model Of Benzoylecgonine Disposition After Cocaine Administration In Humans” Journal of Analytical Toxicology; vol. 15, No. 1; Jan./Feb. 1991; pp. 17-20.
Bagasra et al., “A Potential Vaccine For Cocaine Abuse Prophylaxis”; Immunopharmacology; vol. 23, No. 3; May/Jun. 1992; pp. 173-179.
Bjercke, “Comparison Of Monoclonal And Polyclonal Antibodies To Continue In Nonisotopic And Isotopic Immunoassays”; Journal of Immunological Methods; vol. 96; 1987; pp. 239-246.
Carroll et al., “Chemical Approaches To The Treatment Of Cocaine Abuse”; Pharmaceutical News; vol. 1, No. 2; Jun. 1994; pp. 11-16.
Castro et al., “Characterization of antibodies to Nicotine”, Biochemical Archives, U.S., M.B.R. Press, Inc. vol. 1, No. 3, pp. 173-183, (1985).
Castro et al., “Characterization Of Antibodies To Nicotine”; Biochemical Archives; vol. 1, No. 3; Aug. 1985; pp. 173-183.
Castro et al., “Nicotine Antibodies: Comparison Of Ligand Specificities Of Antibodies Produced Against Two Nicotine Conjugates”; Eur. J. Biochem; 1980; pp. 331-340.
Castro et al., “Nicotine Antibody Production: Comparison Of Two Nicotine Conjugates In Different Animal Species”; Biochemical And Biophysical Research Communications; vol. 67, No. 2, Nov. 17, 1975, pp. 583-589.
Castro et al., “Nicotine Enzyme Immunoassay”; Research Communications In Chemical Pathology And Pharmacology; vol. 51, No. 3; Mar. 1986; pp. 393-404.
Castro et al., “Semi-Rigid And Flexible Linkages In Antibody Production For Determination Of Nicotine”; Biochemical Archives; vol. 1, No. 4; Nov. 1985; pp. 205-214.
Fliniaux et al., “Development Of An Enzyme Innunoassay For The Determination Of Tobacco Alkaloids In Plant Material”, Phytochemical Analysis; vol. 3, No. 5; Sep./Oct. 1992; pp. 223-226.
Gallacher, “A Potential Vaccine For Cocaine Abuse Prophylaxis?”; Immunopharmacology; vol. 27, No. 1; Jan./Feb. 1994; pp. 79-81.
Hieda et al., “Active Immunization Alters The Plasma Nicotine Concentration In Rats”; Immunization and Nicotine Disposition; vol. 283, No. 3; May 14, 1997; pp. 1076-1081.
Killian et al., “Effects Of Passive Immunization Against Morphine On Heroin Self-Administration”; Pharmacology Biochemistry & Behavior; vol. 9, No. 3; 1978; pp. 347-352.
Kovalev et al., Diminishment Of The Effect Of Morphine In Rats Immunized With A Morphine-Protein Conjugated Antigen; Khim. Farm; 1979; pp. 615-618.
Landry et al., “Antibody-Catalyzed Degradation Of Cocaine”; Science; vol. 259; Mar. 26, 1993; pp. 1899-1901.
Langone et al., “Radioimmunoassay Of Nicotine, Cotinine And Y-(3-Pyridyl)-Y-Oxo-N-Methylbutyramide” Methods In Enzymology; vol. 84; 1982; pp. 628-640.
Langone et al., “Nicotine And Its Metabolites. Radioimmunoassays For Nicotine And Cotinine”; Biochemistry vol. 12, No. 24,; 1973; pp. 5025-5030.
Lu et al., “Chemically Unambiguous Peptide Immunogen: Preparation, Orientation And Antigenicty Of Purified Peptide Conjugated To The Multiple Antigen Peptide System”; Molecular Immunology; vol. 28, No. 6; Jun. 1991; pp. 623-630.
Matsushita et al., “Conjugate Of Bovine Serum Albumin With Nicotine”; Biochemical And Biophysical Research Communications; vol. 57, No. 4; Apr. 23, 1974; pp. 1006-1010.
McKenzie et al., “Cholera Toxin B Subunit As A Carrier Protein To Stimulate A Mucosal Immune Response”; Journal Of Immunology; vol. 133, No. 4; Oct. 1984; pp. 1818-1824.
Pentel et al., “Redistribution Of Tricyclic Antidepressants In Rats Using A Drug-Specific Monoclonal Antibody: Dose-Response Relationship”; Drug Metabolism And Disposition; vol. 19, No. 1; Jan./Feb. 1991 pp. 24-28.
Ennifar Sofiane
Fattom Ali Ibrahim
Naso Robert B.
Foley & Lardner LLP
Haq Shafiqul
Le Long V.
Nabi Biopharmaceuticals
LandOfFree
Hapten-carrier conjugates for treating and preventing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hapten-carrier conjugates for treating and preventing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hapten-carrier conjugates for treating and preventing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3732240